165 results on '"Ward, Mark G"'
Search Results
2. Effects of Thiopurine Withdrawal on Vedolizumab-Treated Patients With Ulcerative Colitis: A Randomized Controlled Trial
3. De-escalation from Dose-Intensified Anti-TNF Therapy Is Successful in the Majority of IBD Patients at 12 Months
4. Pharmacist-Driven Therapeutic Infliximab Monitoring at the Point of Care Using Rapidly Assessed Drug Levels in Patients with Inflammatory Bowel Disease
5. Adalimumab Drug Levels at Secondary Loss of Response Do Not Predict Response to Dose-intensification in Crohn's Disease: A Retrospective, International Multicenter Study.
6. Pathogenesis and precision medicine for predicting response in inflammatory bowel disease: advances and future directions
7. Mimics of inflammatory bowel disease: commonly encountered differentials of an uncommon condition.
8. Comparison of Sb2-Infliximab with Originator-Infliximab in the Measurement of Serum Concentrations A Short Communication
9. Adalimumab Drug Levels at Secondary Loss of Response Do Not Predict Response to Dose-intensification in Crohn’s Disease: A Retrospective, International Multicenter Study
10. Can Subcutaneous Infliximab Replace Dose-Intensified Intravenous Administration in Inflammatory Bowel Disease?
11. Therapeutic Drug Monitoring of Subcutaneous Infliximab in Inflammatory Bowel Disease—Understanding Pharmacokinetics and Exposure Response Relationships in a New Era of Subcutaneous Biologics
12. Thiopurines Dosed to a Therapeutic 6-Thioguanine Level in Combination with Adalimumab Are More Effective Than Subtherapeutic Thiopurine-based Combination Therapy or Adalimumab Monotherapy During Induction and Maintenance in Patients with Long-standing Crohnʼs Disease
13. Pharmacist-Driven Therapeutic Infliximab Monitoring at the Point Of Care Using Rapidly Assessed Drug Levels In Patients with Inflammatory Bowel Disease
14. SARS‐CoV‐2 vaccination in patients with inflammatory bowel disease
15. Editorial: total anti‐drug antibodies detected using drug‐tolerant assays during induction with anti‐TNF therapy are associated with treatment failure—out of sight but not out of mind
16. De-escalation from Dose-Intensified Anti-TNF Therapy Is Successful in the Majority of IBD Patients at 12 Months
17. A Single Educational Intervention Improves Pregnancy-Related Knowledge and Emotional Health Among Women With IBD Who Are Pregnant or Wish to Conceive
18. Effects of fiber intake on intestinal pH, transit, and predicted oral mesalamine delivery in patients with ulcerative colitis
19. Thiopurines and their optimization during infliximab induction and maintenance: A retrospective study in Crohn's disease
20. Editorial: balancing safety and efficacy-6-TGN thresholds in NUDT15 intermediate metabolisers treated with thiopurines
21. Practical management of inflammatory bowel disease patients during the COVID ‐19 pandemic: expert commentary from the Gastroenterological Society of Australia Inflammatory Bowel Disease faculty
22. A virtual clinic increases anti‐TNF dose intensification success via a treat‐to‐target approach compared with standard outpatient care in Crohn’s disease
23. Su1883 THROMBOCYTOSIS IN ACUTE INFLAMMATORY BOWEL DISEASE- A USEFUL BIOMARKER?
24. Sa1883 ADALIMUMAB DRUG LEVELS AT SECONDARY LOSS OF RESPONSE IN CROHN'S DISEASE; ARE WE AIMING HIGH ENOUGH? A RETROSPECTIVE, INTERNATIONAL MULTI-CENTRE STUDY.
25. Single Educational Intervention Improves Pregnancy-Related Knowledge and Emotional Health Among Women With IBD Who Are Pregnant or Wish to Conceive.
26. Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease
27. Therapeutic Drug Monitoring of Biologics During Induction to Prevent Primary Non-Response
28. Comparison of Adalimumab Serum Drug Levels When Delivered by Pen Versus Syringe in Patients With Inflammatory Bowel Disease. An International, Multicentre Cohort Analysis
29. Effects of fiber intake on intestinal pH, transit, and predicted oral mesalamine delivery in patients with ulcerative colitis.
30. Thiopurines and their optimization during infliximab induction and maintenance: A retrospective study in Crohn's disease.
31. Editorial: infliximab de-escalation in inflammatory bowel disease using a therapeutic drug monitoring strategy-early promise but more data needed
32. Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure.
33. Therapeutic Drug Monitoring of Biologics During Induction to Prevent Primary Non-Response.
34. Mo1883 - Is There a Difference in Adalimumab Drug Levels According to Pen vs. Syringe use - An International, Multicenter Retrospective Analysis
35. Mo1854 - Pharmacist-Led Proactive Therapeutic Drug Monitoring with Infliximab (Proximo): Utility of and Cost Saving Associated with the use of a Rapid Assay for Assessing Drug Level
36. Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease: current data and future directions
37. Therapeutic drug monitoring in inflammatory bowel disease: too little too early?—comments on the American Gastroenterology Association Guideline
38. Thioguanine in inflammatory bowel disease: Long‐term efficacy and safety
39. A Target 6-Thioguanine Nucleotide Level ≥ 125 is Associated with a Higher Rate and Longer Durability of Response in Infliximab-Thiopurine Combination Therapy: A Retrospective Study in Crohn's Disease Patients
40. Is there a role for thioguanine therapy in IBD in 2017 and beyond?
41. Sa1951 Intrapatient Variability in Adalimumab Drug Levels Within and Across Cycles in Crohn's disease
42. Narrative and Ideological Tension in the Works of Theodor Storm: A Comparative Study of Aquis Submersus and Pole Poppenspäler
43. Prevalence and Risk Factors for Functional Vitamin B12 Deficiency in Patients with Crohnʼs Disease
44. Tu1328 Final Thiopurine Metabolite Levels and Shunter Status Can Be Predicted After Six Weeks of Thiopurine Therapy - Biochemical Outcomes From the EATME Study
45. Sa1183 Adverse Events to Thiopurines Can Be Overcome and the Majority of Patients Respond to Therapy - Clinical Outcomes From the EATME Study
46. Tu1288 The Predictive Value of Early Serum Infliximab, CRP and Faecal Calprotectin Levels Post-First Infliximab Rescue Dose for Acute Severe Colitis: ‘Day 1 to 3 Is Key’
47. Tu1322 A Prospective Evaluation of Adalimumab Drug Levels and Anti-Drug Antibodies Using Two Commercial ELISA and the Influence of 6-Thioguanine Nucleotides Amongst Patients With Inflammatory Bowel Disease
48. Su1206 Association Between Crohn's Disease Activity and Therapeutic Drug Monitoring of Thiopurines and Infliximab Comparing Free and Total Antidrug Antibody Measurement
49. Sa1904 - A Target 6-Thioguanine Nucleotide Level ≥ 125 is Associated with a Higher Rate and Longer Durability of Response in Infliximab-Thiopurine Combination Therapy: A Retrospective Study in Crohn's Disease Patients
50. How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.